1887

Chapter 28 : Biosafety and Viral Gene Transfer Vectors

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Biosafety and Viral Gene Transfer Vectors, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815899/9781555813390_Chap28-1.gif /docserver/preview/fulltext/10.1128/9781555815899/9781555813390_Chap28-2.gif

Abstract:

This chapter provides a general overview of the construction, safety features, and suggested containment level of viral gene transfer vectors in common laboratory use or under development. The discussion of each vector focuses on similarities of the biosafety features and issues arising from the construction and use of these gene transfer systems. The safety assessments and suggested containment levels presented in the chapter can be used to inform the discussions of local institutional biosafety committees (IBCs), investigators, and biosafety professionals, and assist in the assessment of the risks inherent in the use of these vectors in the laboratory. Characteristics of viral systems commonly used for recombinant gene transfer have been provided in the chapter. Replication-defective vector genomes persist in one of two forms in the infected cell: either as an episome or integrated into the host cell genome. In this discussion, an episomal viral vector means that the vector genome remains intact yet is separable from the host cell DNA by physical methods.

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28

Key Concept Ranking

Equine infectious anemia virus
0.5003233
Venezuelan equine encephalitis virus
0.4834583
0.5003233
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Number of PubMed citations found for recombinant viral vectors.

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Number of human gene therapy clinical protocols submitted to NIH Office of Biotechnology by year as of September 2004.

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Summary of gene transfer clinical trial delivery methods through September 2004.

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815899.ch28
1. Ahmed,, R.,, L. A. Morrison,, and D. M. Knipe. 1997. Viral persistence, p. 181–205. In N. Nathanson,, R. Bosenge,, F. Gonzalez-Scarano,, D. E. Griffin,, K. V. Winkelman,, F. A. Murphy, and, H. L. Robinson (ed.), Viral Pathogenesis. Lippincott-Raven Publishers, Philadelphia, Pa.
2. Blouin,, V., N. Brument,, E. Toublanc,, I. Raimbaud,, p. Moullier, and, A. Salvetti. 2004. Improving rAAV production and purification: towards the definition of a scalable process. J. Gene Med. 6:S223–S228.
3. Booth,, M. J.,, A. Mistry,, X. Li,, A. Thrasher, and, R. S. Coffin. 2004. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther. 11:829837.
4. Bourbeau, D., Y. Zeng, and, B. Massie. 2003. Virus-based vectors for gene expression in mammalian cells: adeno-virus, p. 109–123. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
5. Braun,, A. 1999. Biosafety in handling gene therapy vectors, p. 12.0.1–12.7.11. In N. C. Dracopoli,, J. L. Haines,, B. R. Korf,, C. C. Winkelman,, C. E. Seidman,, J. G. Seidman, and, D. R. Smith (ed.), Current Protocols in Human Genetics. Wiley, New York, N.Y.
6. Burton,, E. A.,, Q. Bai,, W. F. Goins,, D. Fink, and, J. C. Glorioso. 2003. Virus-based vectors for gene expression in mammalian cells: herpes simplex virus. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
7. Butel, J. S., and, J. A. Lednicky. 1999. Cell and molecular biology of simian virus 40: implications for human infections and disease. J. Natl. Cancer Inst. 91:119134.
8. Centers for Disease Control and Prevention. 2001. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 50(RR-10):125.
9. Centers for Disease Control and Prevention and National Institutes of Health. 1999. Biosafety in Microbiology and Biomedical Laboratories, 4th ed. U.S. Government Printing Office, Washington, D.C.
10. Centers for Disease Control and Prevention and National Institutes of Health. 2003. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morb. Mortal. Wkly. Rep. 52(RR-7):116.
11. Collaco, R. F., X. Cao., and, J. P. Trempe. 1999. A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 238:397405.
12. Condreay, J. P., and, T. A. Kost. 2003. Virus-based vectors for gene expression in mammalian cells: baculovirus, p. 137–149. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
13. Dang-Tan, D., M. M. Salaheddin,, R. Puntoni, and, E. L. Franco. 2004. Polio vaccines, simian virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23:65356540.
14. Debyser, Z. 2003. Biosafety of lentiviral vectors. Curr. Gene Ther. 3:517525.
15. Delaney, W. E., and, H. C. Isom. 1998. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28:11341146.
16. Dion, L. D.,, J. Fang, and, R., I. Garver, Jr. 1996. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus contaminating recombinant adenovirus stocks. J. Virol. Methods 56:99107.
17. Enders,, J. F.,, J. A. Bell,, J. H. Dingle,, T. Bosenge, Jr.,, M. R. Hilleman,, R. J. Huebner, and, A. M. M. Payne. 1956. “Adenoviruses” group name proposed for new respiratory tract viruses. Science 124:119124.
18. Esposito,, J. J.,, and F. Fenner. 2001. Poxviruses, p. 2885–2922. In D. M. Bosenge,, P. M. Howley,, D. E. Winkelman,, R. A. Lamb,, M. A. Winkelman,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
19. Evans, M. E. 2003. Gene therapy and infection control, p. 262–278. In R. P. Wenzel (ed.), Prevention and Control of Nosocomial Infections, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
20. Evans, M. E., and, J. A. Lesnaw. 2002. Infection control for gene therapy. Clin. Infect. Dis. 35:597605.
21. Fallaux,, F. J.,, A. Bout, I. van der Velde,, D. J. van der Wollenberg,, K. M. Hehir,, J. Bosenge,, C. Auger,, S. J. Cramer,, H. van Ormondt,, A. J. van der Eb,, D. Valerio, and, R. C. Hoeben. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenovirus. Hum. Gene Ther. 9:19091917.
22. Fipaldini, C., B. Bellei, and, N. LaMonica. 1999. Expression of hepatitis C virus cDNA in human hepatoma cell line mediated by a hybrid baculovirus-HCV vector. Virology 255:302311.
23. Fischer,, A.,, H. B. Abina,, A. Thrasher, C. von Kalle,, M. M. Cavazzana-Calvo,, B. D. Stone,, T. H. Rabbitts, and, M. P. McCormack. 2004. LMO2 and gene therapy for severe combined immunodeficiency. N. Engl. J. Med. 350:25262527.
24. Flint,, S. J.,, L. W. Enquist,, R. M. Krug,, V. R. Racaniello, and, A. M. Skalka. 2000. Principles of Virology: Molecular Biology, Pathogenesis, and Control, p. 540–544. ASM Press, Washington, D.C.
25. Fox, J. P., C. E. Hall, and, J. K. Cooney. 1977. The Seattle virus watch, VII. Observations on adenovirus infections. Am. J. Epidemiol. 106:362386.
26. Fraefel,, C., S. Song,, F. Lim,, P. Lang,, L. Yu,, Y. Bosenge,, p. Wild, and, A. I. Geller. 1996. Helper-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70:71907197.
27. Gasmi, M., and, F. Wong-Staal. 2003. Virus-based vectors for gene expression in mammalian cells: lentiviruses, p. 251–264. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
28. Gene Therapy Expert Group, the Committee for Proprietary Medicinal Products (CPMP), European Agency for the Evaluation of Medicinal Products— June 2003 Meeting. 2004. Insertional mutagenesis and oncogenesis: update from non-clinical and clinical studies. J. Gene Med. 6:127129.
29. Goff,, S. 2001. Retroviridae: the retroviruses and their replication, p. 1871–1940. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
30. Gogev, S.,, F. Schynts,, F. Meurens,, I. Bourgot, and, E. Thiry. 2003. Biosafety of herpes virus vectors. Curr. Gene Ther. 3:597611.
31. Green,, M.,, W. S. M. Wold,, and K. H. Brackmann. 1980. Human adenovirus transforming genes: group relationships, integration, expression in transformed cells and analysis of human cancers and tonsils, p. 373–397. In M. Essex,, G. Todaro, and, H. zur Hausen (ed.), Cold Spring Harbor Conference on Cell Proliferation and Viruses in Naturally Occurring Tumors. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
32. Griffin,, D. E. 2001. Alphaviruses, p. 917–962. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
33. Grimm, D. 2002. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 28:146157.
34. Guo, Z. S., and, D. L. Bartlett. 2004. Vaccinia as a vector for gene delivery. Expert Opin. Biol. Ther. 4:901917.
35. Hacein-Bey-Abina,, S., C. Von Kalle,, M. Schmidt,, M. P. McCormack,, N. Wulffratt,, p. Bosenge,, A. Lim,, C. S. Osborne,, R. Bosenge,, E. Morillon,, R. Bosenge,, A. Forster,, p. Bosenge,, J. I. Cohen,, G. de Saint Basile,, U. Alexander Wintergerst,, T. Bosenge,, A. Aurias,, D. Stoppa-Lyonnet,, S. Bosenge,, I. Radford-Weiss,, F. Bosenge,, F. Valensi,, E. Bosenge,, E. Macintyre,, F. Bosenge,, J. Soulier,, L. E. Leiva,, M. Bosenge,, C. Prinz,, T. H. Rabbitts,, F. Le Deist,, A. Fischer, and, M. CavazzanaCalvo. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X-1. Science 302:415419.
36. Harui, A.,, S. Suzuki,, S. Kochanek, and, K. Mitani. 1999. Frequency and stability of chromosomal integration of adenovirus vectors. J. Virol. 73:61416146.
37. Haviernik, P., and, K. D. Bunting. 2004. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Curr. Gene Ther. 4:263276.
38. Hitt, M. M., R. J. Parks, and, F. L. Graham. 1999. Structure and genetic organization of adenovirus vectors, p. 61–86. In T. Friedmann (ed.), The Development of Human Gene Therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
39. Horwitz,, M. S. 2001. Adenoviruses, p. 2301–2326. In D. M. Knipe,, p. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
40. Imperiale, M. J., and, S. Kochanek. 2004. Adenovirus vectors: biology, design and production. Curr. Top. Microbiol. Immunol. 273:335357.
41. Isaacs, S. N. (ed.). 2004. Methods in Molecular Biology, vol. 269. Vaccinia Virus and Poxvirology. Humana Press, Totowa, N.J.
42. Ishii-Watabe,, A., E. Uchida,, A. Iwata,, R. Nagata,, K. Satoh,, K. Bosenge,, M. Murata,, H. Bosenge,, N. Kawasaki,, T. Bosenge,, T. Yamaguchi, and, T. Hayakawa. 2003. Detection of replication-competent adenoviruses spiked into recombinant adenovirus vector products by infectivity PCR. Mol. Ther. 8:10091016.
43. Jarvis, D. L. 1999. Baculovirus expression vectors, p. 389–431. In L. K. Miller (ed.), The Baculoviruses. Plenum Press, New York, N.Y.
44. Johann, S. V.,, J. J. Gibbons, and, B. O’Hara. 1992. GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J. Virol. 66:16351640.
45. Jolly, D. J. 1999. Emerging viral vectors, p. 209–240. In T. Friedmann (ed.), The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
46. Jones,, L., S. Ristow,, T. Yilma, and, B. Moss. 1986. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 319:543.
47. Karlsson,, G. B., and, P. Liljestrom. 2004. Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol. Biol. 246:543557.
48. Knudsen, R. C. 1998. Risk assessment for biological agents in the laboratory. In J. Y. Richmond (ed.), Rational Basis for Biocontainment: Proceedings of the Fifth National Symposium on Biosafety. American Biological Safety Association, Mundelein, Ill.
49. Kost, T. A., and, J. P. Condreay. 2002a. Baculovirus vectors as gene transfer vectors for mammalian cells: biosafety considerations. Appl. Biosafety 7:167169.
50. Kost, T. A., and, J. P. Condreay. 2002b. Recombinant baculoviruses as mammalian cell gene delivery vectors. Trends Biotechnol. 20:173180.
51. Lai, Z., M. Park, and, R. O. Brady. 2002. Design of an HIV-1 lentiviral-based gene-trap vector to detect developmentally regulated genes in mammalian cells. Proc. Natl. Acad. Sci. USA 99:36513656.
52. Laquerre,, S.,, W. F. Goins,, S. Moriuchi,, T. J. Oligino,, D. M. Krisky,, p. Bosenge,, M. K. Soares,, J. B. Winkelman,, J. C. Glorioso, and, D. J. Fink. 1999. Gene-transfer tool: herpes simplex virus vectors, p. 173–208. In T. Friedmann (ed.), The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press, New York, N.Y.
53. Lichtenstein, D. L., and, W. S. M. Wold. 2004. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 11:819829.. (First published 10 September 2004; doi:10.1038/sj.cgt.7700765.)
54. Lin, E., and, J. Nemunaitis. 2004. Oncolytic viral therapies. Cancer Gene Ther. 11:643664.
55. Loeb,, M., I. Zando,, M. C. Orvidas,, A. Bialachowski,, D. Groves, and, J. Mahoney. 2003. Laboratory-acquired vaccinia infection. Can. Commun. Dis. Rep. 29:134136.
56. Lofquist, J. M., N. A. Weimert, and, M. S. Hayney. 2003. Smallpox: a review of clinical disease and vaccination. Am. J. Health Syst. Pharm. 60:749756.
57. Lu, Y. 2004. Recombinant adeno-associated virus as gene delivery vector for gene therapy—a review. Stem Cells Dev. 13:133145.
58. Lundstrom, K. 2003. Virus-based vectors for gene expression in mammalian cells: Semliki Forest virus, p. 207–227. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
59. Makrides, S. C. (ed.). 2003. Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
60. Martinee, K. L.,, D. C. Chuah, and, T. VandenDriessche. 2003. Biosafety of adenoviral vectors. Curr. Gene Ther. 3:527543.
61. Mathiot,, C. C.,, G. Grimaud,, P. Garry,, J. C. Bouquety,, A. Bosenge,, A. M. Daguisy, and, A. J. Georges. 1990. An outbreak of human Semliki Forest virus infections in Central African Republic. Am. J. Trop. Med. Hyg. 42:386393.
62. McVey, D.,, M. Zuber,, D. E. Brough, and, I. Kovesdi. 2003. Adenovirus vector library: an approach to the discovery of gene and protein function. J. Gen. Virol. 84:34173422.
63. Mempel,, M., G. Isa,, N. Klugbauer,, H. Meyer,, G. Wildi,, J. Bosenge,, F. Hofmann, and, H. Hofmann. 2003. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J. Investig. Dermatol. 120:356358.
64. Mickelson, C. A. 2000. Biosafety considerations in rDNA: gene transfer vectors, DNA based vaccines and xenotransplantation, p. 11–41. In J. Y. Richmond (ed.), Anthology of Biosafety: Application of Principles. American Biological Safety Association, Mundelein, Ill.
65. Miller,, A. D. 1997. Development and application of retroviral vectors, p. 437–473, In J. M. Coffin,, S. H. Hughes, and, H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
66. Monahan, P. E.,, K. Jooss, and, M. S. Sands. 2002. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin. Drug Saf. 1:7991.
67. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:1134111348.
68. Moss,, B. 2001. Poxviridae : the viruses and their replication, p. 2849–2884. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
69. Moussatche,, N., M. Tuyama,, S. E. Kato,, A. P. Castro,, B. Bosenge,, R. H. Peralta,, J. M. Winkelman,, C. R. Damaso, and, P. F. Barroso. 2003. Accidental infection of a laboratory worker with vaccinia virus. Emerg. Infect. Dis. 9:724726.
70. Murakami,, P., M. Havenga,, F. Fawaz,, R. Vogels,, G. Marzio,, E. Bosenge,, J. Files,, L. Bosenge,, J. Goudsmit, and, M. McCaman. 2004. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J. Virol. 78:62006208.
71. Muzyczka,, N., and, K. I. Berns. 2001. Parvoviridae : the viruses and their replication, p. 2327–2360. In D. M. Knipe,, p. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
72. Narezkina,, A.,, K. D. Taganov,, S. Letwin,, R. Stoyanova,, J. Hayashi,, C. Bosenge,, A. M. Skalka, and, R. A. Katz. 2004. Genome-wide analyses of avian sarcoma virus integration sites. J. Virol. 78:1165611663.
73. National Institutes of Health. 1993. Appendix D-56 [NIH Guidelines]. National Institutes of Health, Bethesda, Md.
74. National Institutes of Health. 2002. NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines), 59 FR 34496 (July 5, 1994), as amended. [Online: the current amended version can be accessed at http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html.]
75. Oppenshaw,, P. J. M.,, W. H. Alwan,, A. H. Cherrier, and, F. M. Record. 1991. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 338:459.
76. O’Reilly, D. R., L. K. Miller, and, V. A. Luckow. 1994. Baculovirus Expression Vectors: a Laboratory Manual. Oxford University Press, New York, N.Y.
77. Oualikene, W., P. Gonin, and, M. Eliot. 1994. Short and long term dissemination of deletion mutants of adeno-virus in permissive (cotton rat) and non-permissive (mouse) species. J. Gen. Virol. 75:27652768.
78. Paoletti, E. 1996. Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:349353.
79. Parolin, C., and, G. Palù. 2003. Virus-based vectors for gene expression in mammalian cells: retrovirus, p. 231–250. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
80. Pfeifer,, A., and, I. M. Verma. 2001. Virus vectors and their applications, p. 469–492. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
81. Ponnazhagan, S. 2004. Parvovirus vectors for cancer gene therapy. Expert Opin. Biol. Ther. 4:5364.
82. Ponnazhagan,, S., D. Erikson,, W. G. Kearns,, S. Z. Zhou,, p. Bosenge,, X. S. Wang, and, A. Srivastava. 1997. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum. Gene Ther. 8:275284.
83. Recchia, A.,, L. Perani,, D. Sartori,, C. Olgiati, and, F. Mavilio. 2004. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 10:660670.
84. Roizman,, B., and, D. M. Knipe. 2001. Herpes simplex viruses and their replication, p. 2399–2462. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
85. Romano, G., C. Pacilio, and, A. Giordano. 1999. Gene transfer technology in therapy: current applications and future goals. Stem Cells 17:191202.
86. Rowe,, W. P.,, R. J. Huebner,, L. K. Gilmore,, R. H. Parrot, and, T. G. Ward. 1953. Isolation of a cytopathic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84:570573.
87. Rupprecht,, C. E.,, L. Blass,, K. Smith,, L. A. Orciari,, M. Bosenge,, S. G. Whitfield,, R. V. Winkelman,, M. Guerra, and, C. A. Hanlon. 2001. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med. 345:1784.
88. Samulski, R. J.,, M. Sally, and, N. Muzyczka. 1999. Adeno-associated viral vectors, p. 131–172. In T. Friedmann (ed.), The Development of Gene Therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
89. Schlesinger,, S., and, M. J. Schlesinger. 2001. Togaviridae: the viruses and their replication, p. 895–916. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
90. Schroder,, A. R., P. Shinn,, H. Chen,, C. Berry,, J. R. Ecker, and, F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521529.
91. Sepkowitz, K. A. 2003. How contagious is vaccinia? N. Engl. J. Med. 348:439446.
92. Shenk,, T. E. 2001. Adenoviridae: the viruses and their replication, p. 2265–2300. In D. M. Knipe,, P. M. Howley,, D. E. Griffin,, R. A. Winkelman,, M. A. Martin,, B. Roizman, and, S. E. Straus (ed.), Fields Virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, Pa.
93. Spaete, R. R., and, N. Frenkel. 1982. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30:295304.
94. Stanford,, W. L.,, J. B. Cohn,, and S. P. Cordes. 2001. Gene-trap mutagenesis: past, present, and beyond. Nat. Rev. Genet. 2:756768.
95. Strickler,, H. D., P. S. Rosenberg,, S. S. Devesa,, J. Bosenge,, J. F. Fraumeni, and, J. J. Goedert. 1998. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. J. Am. Med. Assoc. 279:292295.
96. Tenenbaum,, L., E. Lehtonen,, and P. E. Monahan. 2003. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr. Gene Ther. 3:545565..
97. Thomas,, C. E., A. Ehrhardt, and, M. A. McKay. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4:346358.
98. Trentin, J. J.,, Y. Yabe, and, G. Taylor. 1962. The quest for human cancer viruses. Science 137:835839.
99. Tufaro, F. 1997. Virus entry: two receptors are better than one. Trends Microbiol. 5:257258.
100. Urabe, M., C. Ding, and, R. M. Kotin. 2002. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13:19351943.
101. VandenDriessche, T., D. Collen, and, M. K. L. Chuah. 2003. Biosafety of onco-retroviral vectors. Curr. Gene Ther. 3:501515.
102. Vanderplassechen, A., and, P. P. Pastoret. 2003. The uses of poxviruses as vectors. Curr. Gene Ther. 3:583595.
103. Wan, Y., and, S. K. Nordeen. 2002. Identification of genes differentially regulated by glucocorticoids and progestins using a Cre/loxP-mediated retroviral promoter-trapping strategy. J. Mol. Endocrinol. 28:177192.
104. Wang,, F.,, D. K. Patel,, J. M. Antonello,, M. W. Washabaugh,, D. C. Kaslow,, J. W. Shiver, and, N. Chirmule. 2003. Development of an adenovirus-shedding assay for the detection of adenovector-based vaccine and gene therapy products in clinical specimens. Hum. Gene Ther. 14:2536.
105. Wang, Y., and, S. Huang. 2000. Adenovirus technology for gene manipulation and functional studies. Drug Discov. Today 5:1016.
106. Willems,, W. R.,, G. Kaluza,, C. B. Boschek,, H. Bauer,, H. Bosenge,, H.-J. Schütz, and, H. Feistner. 1979. Semliki Forest virus: cause of a fatal case of human encephalitis. Science 203:11271129.
107. Wilson, C. A., T. H. Ng, and, A. E. Miller. 1997. Evaluation of recommendation for replicationcompetent retro-virus testing associated with use of retroviral vectors. Hum. Gene Ther. 8:869874.
108. Wivel, N. A., G. P. Gao, and, J. M. Wilson. 1999. Adenovirus vectors, p. 87–110. In T. Friedmann (ed.), The Development of Human Gene Therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
109. Xiao, X. 2003. Virus-based vectors for gene expression in mammalian cells, p. 93–106. In S. C. Makrides (ed.), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V., Amsterdam, The Netherlands.
110. Xiao, X., J. Li, and, R. J. Samulski. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:22242232.

Tables

Generic image for table
TABLE 1

Significant events in rDNA technology

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28
Generic image for table
TABLE 2

Characteristics of viral systems commonly used for recombinant gene transfer

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28
Generic image for table
TABLE 3

Optimal vector characteristics and safety issues

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28
Generic image for table
TABLE 4

Viral vectors and transgene containment

Citation: Kost T, Patrick C, Mickelson C. 2006. Biosafety and Viral Gene Transfer Vectors, p 509-530. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch28

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error